

# COMMONWEALTH UPDATE ON HEALTH AND MEDICAL RESEARCH

## **CHA Research Symposium 2018**

1 June 2018

#### **David Abbott PhD**

Principal Research Scientist
Office of Health and Medical Research



# Australian Health System – 4 x PILLARS


- 1. Guaranteeing Medicare and access to medicines
- 2. Supporting our hospitals
- 3. Prioritising mental health, preventive health and sport, and
- 4. Investing in health and medical research

>\$6 billion over the next five years on research



# How does Australia compare?


#### R&D as a percentage of GDP



17 February 2017 **2** 



# **Commonwealth investment**



17 February 2017 3



#### MEDICAL RESEARCH FUTURE FUND


- dedicated vehicle for priority-driven investment
- endowment fund (\$20b), with capital preserved in perpetuity

2016-17 (\$M)	2017-18 (\$M)	2018-19 (\$M)	2019-20 (\$M)	2020-21 (\$M)
60.9	121.6	214.9	386.4	642.9

- additional and complementary to NHMRC
- Australian Medical Research Advisory Board
- inaugural MRFF STRATEGY and PRIORITIES
- www.health.gov.au/MRFF



# Disbursement projections



24 November 2016 4



# MRFF NHMRC BTF

1. DISCOVERY 2. DEVELOPMENT 3. DELIVERY



#### **CLINICAL TRIALS**

Once a disease target is identified, drugs are designed and tested. Both public and privately funded research are involved.



#### **REGULATORY APPROVAL**

Human trials are completed. FDA approval. Industry is responsible for bringing a drug to market. Safety and evaluation continue after approvals.



IDEA













#### **BASIC RESEARCH**

The majority of the research at this stage is publicly funded at universities, colleges and independent research institutions in every state.







### **Biomedical Translation Fund**

- National Innovation and Science Agenda
- investment in biomedical start-ups that are commercialising discoveries for market success
- for-profit venture fund (>\$500M)
  - combined Commonwealth and private capital
- licensed private sector fund managers
  - OneVentures
  - Brandon Capital Partners
  - BioScience Managers





# **Medical Research Advisory Board**

"ensure the MRFF is enduring and transformative"

### Funding Principles (announced 6 December 2017)

- Contestable processes, peer review, diverse perspectives
- Collaboration across sectors and with end-users
- > Focus on burden and unmet need evidence gaps
- Game-changers balanced with sector improvements

#### 2019-2021 Priorities (consultation from mid -2018)

➤ Broad engagement - consumers, researchers, clinicians, health system managers



### 2017-18 Announcements...

- Australian Brain Cancer Mission \$100m/10 years
  - > research roadmap double survival rates and improve quality of life
  - > MRFF contribution of \$50m, to be matched by co-funding partners
- Clinical Trials \$69m to award in 2017-18 and 2018-19
  - > rare cancers, rare diseases and unmet need 19 trials = \$26m
  - > \$10m targeted call for low survival cancers and diseases
  - > further \$33m for open call in 2018-19
- BioMedTech Horizons
  - ➤ Horizons 1.0 \$5m (precision medicine and 3D printing) MTPConnect
  - ➤ Horizons 2.0 (medtech focus) further \$30m/4 years from 2017-18
- Next Generation Clinical Researchers (+\$70m/5 years)
  - > available via existing NHMRC fellowship schemes x 3
  - > from 2018-19, transition to new Investigator Grants integrated, flexible
- Research Translation Centres (\$55m/3 years)
  - > AHRTCs and CIRHs primed and ready vehicles to tackle health system challenges



# National Health and Medical Industry Growth Plan

- \$1.3 billion total package Budget 2018/19
- Genomics Health Futures Mission (Genomics Mission)
  - \$500M over 10 years
  - clinical flagship studies rare diseases, rare cancers and complex conditions
  - o privacy, legal, social and familial impacts
  - analytical power backed by national standards
  - secure data holdings access, analysis and sharing

First project is a \$20 million trial in pre-conception screening



#### **Genomics Mission – foundational elements**

- National Health Genomics Policy Framework 2017
- ACOLA: The Future of Precision Medicine in Australia 2018
- Large NHMRC grants International Cancer Genome Consortium (ICGC) and Australian Genomics Health Alliance (AGHA)
- State and territory investments, e.g. Queensland Genomics Health Alliance
- International efforts, e.g. Global Alliance for genomics and Health (GA4GH), Global Genomic Medicine Collaborative (G2MC)



# **National Health Genomics Policy Framework**

- COAG Health Council
- aligned policy settings across Australia
- agreed strategic priorities:
  - precision medicine
  - skilled workforce
  - safety and quality
  - financing/cost effectiveness
  - power of data
- national standards: data, research, ethics, legal and delivery

efficient, effective, ethical and equitable – system integration



## **Genomics Mission – next steps**



Steering Committee – Chaired by Professor Ian Fraser

Public Consultation – Operational Plan and options for IT solution

#### **Considerations:**

- Move from disease specific data holdings to federated or national approaches
- Build on strengths by identifying opportunities to scale-up
- Obvious areas are cancer and rare diseases, but what will genomics mean for chronic disease?
- Ethical, legal and social issues are critical, e.g. facilitate data sharing while protecting security and privacy



## **MRFF Strategy and Priorities**

 Health system fully informed by quality health and medical research

## **Strategy 2016-2021**

- Strategic and international horizons
- Data and infrastructure
- Health services and systems
- Capacity and collaboration
- Trials and translation
- Commercialisation

**Priorities 2016-2018** 







# Thank you

17 February 2017 13